RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (CBI) (Nasdaq: CBTE), a contract research organization providing outsourced services in the area of biotechnology discovery and development to companies worldwide, today disclosed that it was a key laboratory in developing the DNA forensics methods used to identify the source of the 2001 anthrax letter attacks that killed five, sickened 17 and caused widespread panic in the days following Sept. 11. CBI carried out thousands of tests over the course of the investigation spanning from early 2002 until the abrupt end in 2008. Since the beginning of the investigation CBI has been under a Non-Disclosure agreement with the FBI and could not disclose its involvement in the case. Recently CBI received notice that the FBI has lifted certain clauses in the agreement and CBI is now able to disclose it’s role in the investigation, in particular the science developed and used at CBI.
